Breaking News
May 3, 2019 - Vaping and Smoking May Signal Greater Motivation to Quit
May 3, 2019 - Dementia looks different in brains of Hispanics
May 3, 2019 - Short-Staffed Nursing Homes See Drop In Medicare Ratings
May 3, 2019 - Study of teens with eating disorders explores how substance users differ from non-substance users
May 3, 2019 - Scientists develop new video game that may help in the study of Alzheimer’s
May 3, 2019 - Arc Bio introduces Galileo Pathogen Solution product line at ASM Clinical Virology Symposium
May 3, 2019 - Cornell University study uncovers relationship between starch digestion gene and gut bacteria
May 3, 2019 - How to Safely Use Glucose Meters and Test Strips for Diabetes
May 3, 2019 - Anti-inflammatory drugs ineffective for prevention of Alzheimer’s disease
May 3, 2019 - Study tracks Pennsylvania’s oil and gas waste-disposal practices
May 3, 2019 - Creating a better radiation diagnostic test for astronauts
May 3, 2019 - Vegans are often deficient in these four nutrients
May 3, 2019 - PPDC announces seed grants to develop medical devices for children
May 3, 2019 - Study maps out the frequency and impact of water polo head injuries
May 3, 2019 - Research on Reddit identifies risks associated with unproven treatments for opioid addiction
May 3, 2019 - Good smells may help ease tobacco cravings
May 3, 2019 - Medical financial hardship found to be very common among people in the United States
May 3, 2019 - Researchers develop multimodal system for personalized post-stroke rehabilitation
May 3, 2019 - Study shows significant mortality benefit with CABG over percutaneous coronary intervention
May 3, 2019 - Will gene-editing of human embryos ever be justifiable?
May 3, 2019 - FDA Approves Dengvaxia (dengue vaccine) for the Prevention of Dengue Disease in Endemic Regions
May 3, 2019 - Why Tonsillitis Keeps Coming Back
May 3, 2019 - Fighting the opioid epidemic with data
May 3, 2019 - Maggot sausages may soon be a reality
May 3, 2019 - Deletion of ATDC gene prevents development of pancreatic cancer in mice
May 2, 2019 - Targeted Therapy Promising for Rare Hematologic Cancer
May 2, 2019 - Alzheimer’s disease is a ‘double-prion disorder,’ study shows
May 2, 2019 - Reservoir bugs: How one bacterial menace makes its home in the human stomach
May 2, 2019 - Clinical, Admin Staff From Cardiology Get Sneak Peek at Epic
May 2, 2019 - Depression increases hospital use and mortality in children
May 2, 2019 - Vicon and NOC support CURE International to create first gait lab in Ethiopia
May 2, 2019 - Researchers use 3D printer to make paper organs
May 2, 2019 - Viral infection in utero associated with behavioral abnormalities in offspring
May 2, 2019 - U.S. Teen Opioid Deaths Soaring
May 2, 2019 - Opioid distribution data should be public
May 2, 2019 - In the Spotlight: “I’m learning every single day”
May 2, 2019 - 2019 Schaefer Scholars Announced
May 2, 2019 - Podcast: KHN’s ‘What The Health?’ Bye-Bye, ACA, And Hello ‘Medicare-For-All’?
May 2, 2019 - Study describes new viral molecular evasion mechanism used by cytomegalovirus
May 2, 2019 - SLU study suggests a more equitable way for Medicare reimbursement
May 2, 2019 - Scientists discover first gene involved in lower urinary tract obstruction
May 2, 2019 - Researchers identify 34 genes associated with increased risk of ovarian cancer
May 2, 2019 - Many low-income infants receive formula in the first few days of life, finds study
May 2, 2019 - Global study finds high success rate for hip and knee replacements
May 2, 2019 - Taking depression seriously: What is it?
May 2, 2019 - With Head Injuries Mounting, Will Cities Put Their Feet Down On E-Scooters?
May 2, 2019 - Scientists develop small fluorophores for tracking metabolites in living cells
May 2, 2019 - Study casts new light into how mothers’ and babies’ genes influence birth weight
May 2, 2019 - Researchers uncover new brain mechanisms regulating body weight
May 2, 2019 - Organ-on-chip systems offered to Asia-Pacific regions by Sydney’s AXT
May 2, 2019 - Adoption of new rules drops readmission penalties against safety net hospitals
May 2, 2019 - Kids and teens who consume zero-calorie sweetened beverages do not save calories
May 2, 2019 - Improved procedure for cancer-related erectile dysfunction
May 2, 2019 - Hormone may improve social behavior in autism
May 2, 2019 - Alzheimer’s disease may be caused by infectious proteins called prions
May 2, 2019 - Even Doctors Can’t Navigate Our ‘Broken Health Care System’
May 2, 2019 - Study looks at the impact on criminal persistence of head injuries
May 2, 2019 - Honey ‘as high in sugars as table sugar’
May 2, 2019 - Innovations to U.S. food system could help consumers in choosing healthy foods
May 2, 2019 - FDA Approves Mavyret (glecaprevir and pibrentasvir) as First Treatment for All Genotypes of Hepatitis C in Pediatric Patients
May 2, 2019 - Women underreport prevalence and intensity of their own snoring
May 2, 2019 - Concussion summit focuses on science behind brain injury
May 2, 2019 - Booker’s Argument For Environmental Justice Stays Within The Lines
May 2, 2019 - Cornell research explains increased metastatic cancer risk in diabetics
May 2, 2019 - Mount Sinai study provides fresh insights into cellular pathways that cause cancer
May 2, 2019 - Researchers to study link between prenatal pesticide exposures and childhood ADHD
May 2, 2019 - CoGEN Congress 2019: Speakers’ overviews
May 2, 2019 - A new strategy for managing diabetic macular edema in people with good vision
May 2, 2019 - Sagent Pharmaceuticals Issues Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP, 60mg/2mL (30mg per mL) Due to Lack of Sterility Assurance
May 2, 2019 - Screen time associated with behavioral problems in preschoolers
May 2, 2019 - Hormone reduces social impairment in kids with autism | News Center
May 2, 2019 - Researchers synthesize peroxidase-mimicking nanozyme with low cost and superior catalytic activity
May 2, 2019 - Study results of a potential drug to treat Type 2 diabetes in children announced
May 2, 2019 - Multigene test helps doctors to make effective treatment decisions for breast cancer patients
May 2, 2019 - UNC School of Medicine initiative providing unique care to dementia patients
May 2, 2019 - Nestlé Health Science and VHP join forces to launch innovative COPES program for cancer patients
May 2, 2019 - Study examines how our brain generates consciousness and loses it during anesthesia
May 2, 2019 - Transition Support Program May Aid Young Adults With Type 1 Diabetes
May 2, 2019 - Study shows how neutrophils exacerbate atherosclerosis by inducing smooth muscle-cell death
May 2, 2019 - Research reveals complexity of how we make decisions
Antiviral treatment improves survival for kidney transplant recipients infected with HBV or HCV

Antiviral treatment improves survival for kidney transplant recipients infected with HBV or HCV

Prior to the development of antiviral therapy, kidney transplant recipients infected with either hepatitis B (HBV) or hepatitis C (HCV) experienced poor outcomes. In a new study in the Journal of Hepatology, published by Elsevier, researchers report favorable 10-year survival rates for patients with HBV and/or HCV treated with antiviral agents and advise that antiviral therapy should be systematically offered to all HBV and HCV patients in line with international recommendations.

Renal transplantation is currently the best treatment for patients with end-stage renal disease (ESRD) because it significantly improves survival compared to patients who remain on hemodialysis. Since the 1990s, antiviral therapy using nucleos(t)ide analogs like adefovir, lamivudine, tenofovir, and entecavir, has benefited HBV-infected patients by preventing viral replication in infected cells. Interferon-based therapy has been rarely used in HCV-infected patients because it increases the risk of transplant rejection. Although the prevalence of HBV and HCV infection in patients with ESRD has significantly declined over time, it remains at least four times higher than in the general population.

“With the improvement of HBV treatment in the last two decades and the development of new treatments against HCV, an update of data in large cohorts of kidney transplant recipients with long-term follow-up was warranted,” explained lead investigator Philippe Mathurin, MD, PhD, CHRU de Lille, Chief, Service des maladies de l’appareil digestif, Université Lille 2 and Inserm U795, Lille, France.

To reassess the impact of HBV and HCV on patient and kidney transplant graft survival, researchers analyzed records of more than 30,000 kidney transplant recipients using the French national database CRISTAL, including 575 recipients with HBV, 1,060 with HCV, and 29,798 who were free from infection. The first step of this study compared prognoses in these three groups and confirmed a poorer prognosis in HCV-infected patients than in non-infected patients. In contrast, there was no significant difference in patient and graft survival in HBV-infected patients compared with non-infected patients.

In the second step of this study, a random analysis of the medical records of 184 HBV and 504 HCV patients showed a control of viral replication in 94 percent and 35 percent of cases, respectively. For each kidney transplant recipient with HCV with detectable or undetectable HCV RNA, researchers randomly selected one to four matched controls from the 29,797 non-infected patients using the following matching criteria: gender, age, duration of dialysis, duration of cold ischemia, and year of transplantation. This analysis provided evidence that HBV chronic infection, which previously had a negative impact on patient and survival in kidney transplant patients, no longer influences patient or graft survival due to the control of viral replication related to the extensive use of nucleos(t)ide analogs. In contrast, HCV chronic infection still negatively impacts 10-year patient and graft survival. However, HCV’s negative influence is counteracted by sustained viral suppression, since it is no longer observed in kidney transplant recipients with undetectable HCV RNA.

“The control of viral replication is a key factor in kidney transplant recipients,” commented Dr. Mathurin. “The present results suggest, in line with international and KDIGO (Kidney Disease: Improving Global Outcomes) guidelines, that antiviral therapy should be systematically offered to HBV- and/or HCV-infected kidney transplant recipients or candidates to prevent the impact of chronic viral replication. Antiviral therapy with nucleos(t)ide analogs or direct antiviral agents should systematically be proposed, considering the major impact on patient and graft survival.”

Source:

https://www.elsevier.com/

Tagged with:

About author

Related Articles